ClinicalTrials.gg
CompletedNCT05378945Updated Apr 25, 2023

Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease

A Phase 3 interventional study of Varenicline Tartrate Nasal Spray and Placebo (vehicle) in Dry Eye Disease, sponsored by Corxel Pharmaceuticals. Completed at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-25.

Sponsored by Corxel Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing varenicline in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. Varenicline · Dry Eye Syndromes.

Enrollment
2nd of 13
340 · median 60
Started
2022
with 2 others
Phase 3
4 of 13
none open now
Registered
8th of 13
by date
Lead sponsor
2 of 13
Corxel Pharmaceuticals

Among the 13 studies testing varenicline in Dry Eye Syndromes, this one is the 2nd largest by enrollment, is one of 3 that started in 2022, is one of 4 in phase 3, and was the 8th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 13 studies testing varenicline in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing varenicline in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and effectiveness of OC-01 (varenicline solution) Nasal Spray as compared to placebo (vehicle) on signs and symptoms of dry eye disease.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

Keywords

  • OC-01
  • Dry Eye Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 6 months prior to the Screening Visit

Exclusion criteria

Exclusion Criteria:

  • Have had any intraocular surgery (such as cataract surgery) or extraocular surgery in either eye within three months or refractive surgery (e.g., laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within 12 months of the Screening Visit
  • Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, acute conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with DED are allowed.
  • Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study (e.g., current systemic infection, uncontrolled disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
  • Have a known to any of the procedural agents or product components
  • Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
340 participants (actual)

Study arms

  • Experimental
    OC-01

    Drug: Varenicline Tartrate Nasal Spray

  • Placebo comparator
    Placebo

    Drug: Placebo (vehicle)

Interventions

  • Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days

    Also known as: OC-01 (varenicline solution) Nasal Spray

  • DrugPlacebo (vehicle)

    Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days

06

What researchers measure

Primary outcomes

  1. Schirmer's Test Score

    Percentage of subjects who achieve ≥10 mm improvement in Schirmer's Test Score from baseline

    Time frame: 28 days

Secondary outcomes

  1. Mean change from Baseline in Schirmer's Test Score (STS)

    Schirmer's test scores are from 0-35 mm where a higher score is indicative of a better outcome.

    Time frame: 28 days

  2. Mean change from Baseline in Eye Dryness Score (EDS)

    Eye dryness score is assessed on a visual analogue scale with scores ranging from 0 to 100 (0=no discomfort; 100=maximal discomfort) and lower scores indicate a better outcome

    Time frame: 28 days/ 14 days/ 7days

Other outcomes

  1. Mean change from Baseline in Total Corneal Fluorescein Staining

    Time frame: 28 days

  2. Mean change from Baseline in Inferior Corneal Fluorescein Staining

    Time frame: 28 days

  3. Mean change from Baseline in Nasal Corneal Fluorescein Staining

    Time frame: 28 days

  4. Mean change from Baseline in Temporal Corneal Fluorescein Staining

    Time frame: 28 days

  5. Mean change from Baseline in Central Corneal Fluorescein Staining

    Time frame: 28 days

  6. Mean change from Baseline in Superior Corneal Fluorescein Staining

    Time frame: 28 days

07

Study locations

20 sites
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui, China
  • Beijing Tongren Hospital
    Beijing, Beijing 100730, China
  • Beijing Hospital
    Beijing, Beijing, China
  • Peking University Third Hospital
    Beijing, Beijing, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou, China
  • Shijiazhuang People's Hospital
    Shijiazhuang, Hebei, China
  • Hebei Eye Hospital
    Xingtai, Hebei, China
  • The First Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang, China
  • Henan Eye Hospital
    Zhengzhou, Henan, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Wuhan Aier Eye Hospital Hankou Hospital
    Wuhan, Hubei, China
  • Nanjing First Hospital
    Nanjing, Jiangsu, China
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin, China
  • Eye Hospital of Shandong First Medical University
    Jinan, Shandong, China
  • Weifang Eye Hospital
    Weifang, Shandong, China
  • Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
  • Tongji Hospital of Tongji University
    Shanghai, Shanghai, China
  • Tianjin Medical University Eye Hospital
    Tianjin, Tianjin, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Apr 2023, 8 months.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 8 months is below that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2022
First posted
May 18, 2022
StartActual
Jul 22, 2022
Primary completionActual
Apr 4, 2023
CompletionActual
Apr 4, 2023
Last update
Apr 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05378945
Lead sponsor
Corxel Pharmaceuticals
Responsible party
Sponsor
First posted
May 18, 2022
Start date
Jul 22, 2022
Primary completion
Apr 4, 2023
Completion
Apr 4, 2023
Last update
Apr 25, 2023

Study contacts

JIE, Doctor
principal investigator · Beijing Tongren Hospital
DING
study director · Corxel Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion